Search - tctmd.com

Displaying 541 - 560 of 639

Sort: Relevancy | Date

News Industry News

OrbusNeich’s Combo Dual Therapy Stent™ Featured During Symposium at Angioplasty Summit TCTAP 2012

April 25, 2012

News Industry News

OrbusNeich’s Genous™ Stent Achieves Complete Endothelialization at Two Weeks

April 20, 2012

Presentation GI2 2012

Drug-Eluting Balloon: Clinical Evidence for In-Stent Restenosis

Presenter: Marco V. Wainstein

April 12, 2012

News Daily News

DEB-AMI Published: Drug-Eluting Balloon Fails to Impress in STEMI

April 12, 2012

Presentation GI2 2012

The Controversy: DES vs DEB for In-Stent Restenosis

Presenter: Pedro A. Lemos

April 11, 2012

Presentation GI2 2012

Focus on In-Stent Restenosis: Imaging to Guide the Best Treatment

Presenter: Jose Ribamar Costa

April 11, 2012

News Daily News

Metal Allergy No Barrier to Stent Use

April 10, 2012

News Conference News ACC 2012

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Yael L. Maxwell

April 02, 2012

News Industry News

Data Presented at ACC.12 Demonstrate that OrbusNeich’s Genous™ Stent is Feasible and Safe in STEMI Patients

March 27, 2012

News Conference News ACC 2012

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

March 26, 2012

News Conference News ACC 2012

Anti-inflammatory Lowers In-Stent Late Loss After BMS Implantation

March 24, 2012

News Daily News

Drug-Eluting Balloon Continues Strong Showing in SFA Lesions

Jason Kahn

March 22, 2012

News Daily News

Surgery Safer Than Endovascular Procedure for Form of Chronic Arteritis

Jason Kahn

March 21, 2012

News Daily News

El Celecoxib Aumenta la Eficacia de los SLF a un determinado Coste Clínico

March 15, 2012

News Daily News

Celecoxib Enhances DES Efficacy, But at Clinical Cost

March 15, 2012

News Daily News

SES Effective for Both Focal, Diffuse DES Restenosis

March 13, 2012

News Daily News

El SLS es Efectivo contra la Reestenosis tanto Focal como Difusa del SLF

March 13, 2012

Presentation

Randomized Trial of Optimal Treatment Strategies for In-Stent Restenosis After DES Implantation

Presenter: H. Song

March 12, 2012

News Daily News

Restenotic Pattern After Femoropopliteal Stenting Predicts Recurrence

March 06, 2012

News Daily News

It’s DESTINY: DES Superior to BMS for Below-the-Knee Lesions

Jason Kahn

March 06, 2012

Advertisement

OrbusNeich’s Combo Dual Therapy Stent™ Featured During Symposium at Angioplasty Summit TCTAP 2012

OrbusNeich’s Genous™ Stent Achieves Complete Endothelialization at Two Weeks

Drug-Eluting Balloon: Clinical Evidence for In-Stent Restenosis

DEB-AMI Published: Drug-Eluting Balloon Fails to Impress in STEMI

The Controversy: DES vs DEB for In-Stent Restenosis

Focus on In-Stent Restenosis: Imaging to Guide the Best Treatment

Metal Allergy No Barrier to Stent Use

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Data Presented at ACC.12 Demonstrate that OrbusNeich’s Genous™ Stent is Feasible and Safe in STEMI Patients

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

Anti-inflammatory Lowers In-Stent Late Loss After BMS Implantation

Drug-Eluting Balloon Continues Strong Showing in SFA Lesions

Surgery Safer Than Endovascular Procedure for Form of Chronic Arteritis

El Celecoxib Aumenta la Eficacia de los SLF a un determinado Coste Clínico

Celecoxib Enhances DES Efficacy, But at Clinical Cost

SES Effective for Both Focal, Diffuse DES Restenosis

El SLS es Efectivo contra la Reestenosis tanto Focal como Difusa del SLF

Randomized Trial of Optimal Treatment Strategies for In-Stent Restenosis After DES Implantation

Restenotic Pattern After Femoropopliteal Stenting Predicts Recurrence

It’s DESTINY: DES Superior to BMS for Below-the-Knee Lesions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content